20/20 BioLabs Q2 Revenue Jumps 36.5% as Cancer Test Sales Hit Record
AIDX sits 42% above its 52-week low of $0.401 on light trading volume (0.3× avg).
Summary
20/20 BioLabs reported Q2 2026 revenue of $0.7 million, up 36.5% year-over-year, driven by a 47.1% increase in OneTest cancer screening revenue. Gross margin expanded to 41.7% from 30.5%, and the company eliminated all convertible note debt while cash improved to $4.5 million. New state contracts in Vermont and Maryland, plus a retail pilot with Giant Food, signal expanding distribution. However, the company remains reliant on dilutive financing and faces Nasdaq delisting risk, with a standstill agreement limiting near-term conversions. The record quarterly cancer test revenue and improving margins are positive, but the small revenue base and ongoing losses temper the significance.
At the time of this announcement, AIDX was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.40 to $50.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.